Exiris makes use of several platform technologies for target identification and validation. In addition, Exiris is developing its own antibody and drug conjugate technologies: Cancer stem cell platform, Drug conjugate technology and Antibody technologies.

read more


Exiris provides contract research services and collaborative development agreements using its innovative technology platforms: CSC Platform, Target ID, Drug-Conjugate platform, Custom human mAb production, Biomarker discovery and (…)

read more

New data presented at the 35th European Peptide Symposium, 35EPS, Dublin 26th-31st August 2018

Data are presented on novel cryptophycin-based peptide conjugates for tumor targeting, generated in the context of the Horizon 2020 MAGICBULLET project... Read More →

Contact us

Exiris srl

Via Castel Romano 100
00128 Roma RM – Italy

Legal address:
Via Savona 6
00182 Rome – Italy

+39 06 50576530